When the immune system mistakenly attacks healthy cells in both the skin and joints, the result is psoriatic arthritis—a challenging condition that affects approximately 1 million Americans.

(Bloomberg) — The S&P 500 stock index (^GSPC) has dropped to a level where long-term investors are starting to buy the dip, according to Goldman Sachs Group Inc. partner John Flood. The US stock ...

he later revealed that he actually suffers from psoriatic arthritis - a chronic condition characterised by joint pain, swelling and stiffness, according to the NHS. Over the past year, Adam has ...

Investors suffering through this brutal market sell-off may have a reason for hope. History suggests that US stocks tend to rebound strongly after big crashes. A strategy chief says to expect a ...

Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, creating a condition that challenges patients and clinicians alike.

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...

Psoriatic arthritis leads to stiffness, pain and swelling in and around the joints. Credit: Oporty786 / Shutterstock. US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive ...

Broadcom's XPU business is poised to boom over the next few years. The stock trades at a premium to the broader market. Tariffs could affect demand for its XPUs once they're in place for ...

Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related symptoms of arthritis. PsA is an autoimmune disease ...

Objectives: To carry out a multi-modal assessment of heterogeneity of ST obtained through US-guided biopsies from patients with Psoriatic Arthritis (PsA), across different disease phases. Methods: 397 ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...